Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

MEDIA · The MEtabolic Road to DIAstolic Heart Failure

FP7Status: CLOSED1 January 201130 June 2016EU funding €11,971,721

More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements contribute to DHF; 2) how diagnostic algorithms for DHF can be improved by assessing metabolic risk; 3) how correction of metabolic risk can open new therapeutic perspectives for DHF.Hereto MEDIA will: 1) Expose animal models of DHF to intense metabolic risk in order to accelerate DHF development. 2) Perform mechanistic studies in cardiomyocytes derived from DHF animal models or from DHF patients. Because of the acquired nature of metabolic risk, these studies will focus on posttranslational modifications of proteins and on epigenetic control of hypertrophy development. Their relevance for global LV function will also be appraised; 3) Perform mechanistic studies on myocardial collagen synthesis, which is enhanced by metabolic risk, and execute a phase II trial in DHF with cardiac specific antifibrotic therapy; 4) Explore the use of biomarkers as premorbid identifiers of DHF in existing cohorts of patients exposed to metabolic risk; 5) Prospectively test biomarkers and arterial stiffening, which is accelerated by metabolic risk, for their diagnostic potential in a large DHF cohort; 6) Assess myocardial metabolic substrate preference with modern imaging techniques and improve diastolic LV dysfunction through modified substrate utilization in a phase II trial.Expected results of MEDIA are: 1) Identification of metabolic risk-related mechanisms as therapeutic targets; 2) Improved diagnostic algorithms through inclusion of biomarkers and arterial stiffness tests. 3) Novel treatments consisting of modified myocardial substrate utilization and myocardial antifibrotic therapy.

Consortium · 22 organisations

coordinator

STICHTING AMSTERDAM UMC

NL

participant

UNIVERSITEIT ANTWERPEN

BE · €554,711

participant

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

IE · €539,161

participant

STICHTING VU

NL · €1,705,696

participant

DIGNA BIOTECH, S.L

ES · €52,166

participant

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

ES · €788,551

participant

DEBRECENI EGYETEM

HU · €499,783

participant

FONDATION TRANSPLANTATION

FR · €975,271

participant

UNIVERSITEIT MAASTRICHT

NL · €1,053,750

participant

UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO

IT · €532,472

participant

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

NL

participant

RUHR-UNIVERSITAET BOCHUM

DE · €916,945

participant

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

DE · €772,260

participant

OXI GEN LAB SRL

IT

participant

UNIVERSITETET I OSLO

NO · €500,147

participant

UNIVERSITATSKLINIKUM HEIDELBERG

DE · €127,800

participant

UNIVERSIDADE DO PORTO

PT · €811,719

participant

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL · €497,400

participant

UNIVERSITA DEGLI STUDI DI PERUGIA

IT · €524,516

participant

UNIVERSITA DEGLI STUDI DI BRESCIA

IT · €496,231

participant

PLURI BIOTECH LTD

IL · €92,955

participant

CARDIFF UNIVERSITY

UK · €530,187

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.